 |
PDBsum entry 3l5c
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Structure of bace bound to sch723871
|
|
Structure:
|
 |
Beta-secretase 1. Chain: a, b. Synonym: beta-site amyloid precursor protein cleaving enzyme 1, beta- site app cleaving enzyme 1, membrane-associated aspartic protease 2, memapsin-2, aspartyl protease 2, asp 2, asp2. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: bace, bace1, kiaa1149. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Resolution:
|
 |
|
1.80Å
|
R-factor:
|
0.196
|
R-free:
|
0.223
|
|
|
Authors:
|
 |
C.Strickland,Z.Zhu
|
|
Key ref:
|
 |
Z.Zhu
et al.
(2010).
Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation.
J Med Chem,
53,
951-965.
PubMed id:
|
 |
|
Date:
|
 |
|
21-Dec-09
|
Release date:
|
16-Feb-10
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P56817
(BACE1_HUMAN) -
Beta-secretase 1 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
501 a.a.
387 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
J Med Chem
53:951-965
(2010)
|
|
PubMed id:
|
|
|
|
|
| |
|
Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation.
|
|
Z.Zhu,
Z.Y.Sun,
Y.Ye,
J.Voigt,
C.Strickland,
E.M.Smith,
J.Cumming,
L.Wang,
J.Wong,
Y.S.Wang,
D.F.Wyss,
X.Chen,
R.Kuvelkar,
M.E.Kennedy,
L.Favreau,
E.Parker,
B.A.McKittrick,
A.Stamford,
M.Czarniecki,
W.Greenlee,
J.C.Hunter.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
A number of novel amidine containing heterocycles were designed to reproduce the
unique interaction pattern, revealed by X-ray crystallography, between the
BACE-1 catalytic diad and a weak NMR screening hit (3), with special attention
paid to maintaining the appropriate basicity and limiting the number of
H-bonding donors of these scaffolds. The iminohydantoin cores (10 and 23) were
examined first and found to interact with the catalytic diad in one of two
binding modes (A and B), each with the iminohydantoin core flipped 180 degrees
in relation to the other. The amidine structural motif within each core forms a
bidentate interaction with a different aspartic acid of the catalytic diad. Both
modes reproduced a highly conserved interaction pattern between the inhibitors
and the catalytic aspartates, as revealed by 3. Potent iminohydantoin BACE-1
inhibitors have been obtained, validating the molecular design as aspartyl
protease catalytic site inhibitors. Brain penetrant small molecule BACE
inhibitors with high ligand efficiencies have been discovered, enabling multiple
strategies for further development of these inhibitors into highly potent,
selective and in vivo efficacious BACE inhibitors.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
C.W.Murray,
and
T.L.Blundell
(2010).
Structural biology in fragment-based drug design.
|
| |
Curr Opin Struct Biol,
20,
497-507.
|
 |
|
|
|
|
 |
L.B.Salum,
and
N.F.Valadares
(2010).
Fragment-guided approach to incorporating structural information into a CoMFA study: BACE-1 as an example.
|
| |
J Comput Aided Mol Des,
24,
803-817.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |